Home / Deep Research / Sezary Syndrome

Sezary Syndrome

Sezary Syndrome Deep Research Notes

OpenAI MONDO:0017844

Sezary Syndrome Deep Research Notes

Modeling decisions

  • Per cancer curation guidance from dismech issue #1198, this curation treats Sezary syndrome as a single disease-level mechanism graph rather than trying to make every ontology child or staging bucket its own dismech page.
  • disease_term is MONDO-first: MONDO:0017844 Sezary syndrome.
  • NCIT grounding was added wherever the current schema supports cancer-specific terms directly: disease-context term NCIT:C3366 Sezary Syndrome, parent context NCIT:C3467 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, histopathology findings such as NCIT:C36722 Sezary Cell and NCIT:C39621 Cerebriform Lymphocyte, biomarker NCIT:C74625 Sezary Cell Count, biomarker NCIT:C171048 KIR3DL2 Positive, and oncology-specific intervention terms such as NCIT:C62729 Extracorporeal Photopheresis and NCIT:C46089 Allogeneic Hematopoietic Stem Cell Transplantation.
  • I did not create separate disorder files for nonerythrodermic Sezary syndrome, B-stage strata, or large-cell transformation. Those are presentation, staging, or progression facets, not separate disease-level causal programs.
  • I therefore omitted has_subtypes in the YAML. For this disease slice, adding pseudo-subtypes would have created ontology noise without improving the mechanism graph.

Disease identity and ontology grounding

  • MONDO disease anchor: MONDO:0017844 Sezary syndrome.
  • NCIT disease grounding for cancer curation context: NCIT:C3366 Sezary Syndrome.
  • NCIT parent disease context: NCIT:C3467 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma.
  • Core cell-type grounding used in the graph: CL:0000904 central memory CD4-positive, alpha-beta T cell.
  • Core biological-process grounding used in the graph:
  • GO:0072678 T cell migration
  • GO:0007259 cell surface receptor signaling pathway via JAK-STAT
  • GO:0050852 T cell receptor signaling pathway
  • GO:0008283 cell population proliferation
  • GO:0002710 negative regulation of T cell mediated immunity

Key literature takeaways used in the YAML

Definition and diagnosis

  • PMID:34165432 gives the operational disease-defining triad and the classic circulating CD4+/CD8- phenotype with loss of CD7 and/or CD26.
  • PMID:31487384 shows that KIR3DL2 materially improves early diagnosis and blood staging, especially in lymphopenic patients.
  • PMID:28709694 argues that early Sezary syndrome can be missed when erythroderma is absent and supports blood PCR for monoclonal T-cell receptor rearrangement plus flow cytometry in suspicious refractory dermatitis.

Cell of origin and trafficking biology

  • PMID:20484084 supports the central-memory T-cell model for Sezary syndrome and contrasts it with mycosis fungoides.
  • PMID:15727636 anchors the skin/blood/lymph-node recirculation program through CCR4, CCR10, and CCR7.

Core oncogenic mechanisms

  • PMID:26415585 is the main disease-genomics anchor for this entry:
  • recurrent ARID1A loss and broader chromatin-remodeling defects
  • recurrent PLCG1 gain-of-function mutations
  • recurrent JAK1, JAK3, STAT3, and STAT5B lesions
  • explicit therapeutic rationale for JAK/STAT pathway inhibition
  • PMID:29204699 supports downstream immune dysfunction through expanded suppressive T-cell populations in Sezary syndrome.

Histopathology and phenotype

  • PMID:6651315 supports the classic skin-biopsy pattern of atypical lymphoid cells with cerebriform nuclei.
  • PMID:31489115 supports pruritic inflammatory disease burden and immune dysfunction in a modern human-sample transcriptomic study.
  • PMID:29026585 supports palmoplantar keratoderma as a clinically useful Sezary clue.

Therapy

  • PMID:34478581 supports extracorporeal photopheresis as a blood- and skin-active treatment in real-world SS/MF practice.
  • PMID:11331325 supports oral bexarotene as effective systemic CTCL therapy.
  • PMID:25605368 supports mogamulizumab, with stronger response rates in Sezary syndrome than in mycosis fungoides and especially strong blood responses.
  • PMID:31532724 supports pembrolizumab activity in advanced relapsed/refractory MF/SS.
  • PMID:25068422 supports allogeneic hematopoietic cell transplantation as the main potentially curative option in advanced MF/SS.

Important research not fully promoted into the YAML graph

  • PMID:38170178 shows that Staphylococcus aureus enterotoxins can induce drug resistance in primary malignant T cells from patients with Sezary syndrome through TCR, NF-kappaB, and JAK/STAT-associated programs. I kept this in research notes instead of making it a core disease node because it is a clinically important resistance modifier, but not the cleanest disease-defining upstream program for the base Sezary syndrome graph.
  • PMID:25802883 reports a CTLA4:CD28 fusion in an advanced Sezary syndrome case with rapid clinical response to ipilimumab. This is mechanistically interesting but currently better treated as a rare precision-oncology exception than as a disease-level canonical node.
  • PMID:25981000 and PMID:28709694 support nonerythrodermic/early Sezary presentations. Per #1198, these were not split into a separate disease file because they are presentation variants rather than a separate causal program.

Expected validation-sensitive points

  • The triad and blood-burden snippets use typography from PubMed abstracts, including the multiplication sign and micro symbol; these should be preserved exactly for reference validation.
  • NCIT disease-level mappings were handled through schema-supported NCIT uses (findings, biomarkers, treatment terms, agents) plus this research note because the current DiseaseMappings container only exposes explicit mondo_mappings, not ncit_mappings.